Letter

Excerpt: “Today, PBMs manage prescription drug benefits on behalf of a wide array of entities – employer-sponsored health plans, health maintenance organizations, Medicaid managed care plans, and Medicare Part D plans. In fact, a February 2016 report estimated PBMs serve 266 million Americans—most of whom are enrolled in private health plans—and can save plan sponsors significant money on drug benefit costs using a wide range of tools. This study also estimated that the use of these tools will save a total of $654 billion across plan sponsors and members, Medicare...

Excerpt: “Through its public hearings, the committee has heard differing views from experts on the extent to which consolidation is a cost driver in the Medicare program and the degree to which payment policies of the Medicare program encourage such consolidation. Some have questioned the merit of concerns over consolidation and have instead highlighted the beneficial efficiencies and economies of scale that can be accomplished through consolidation. For example, in testimony before the Energy and Commerce Health Subcommittee on May 21, 2014, during a hearing entitled ‘Keeping the Promise: Site-of-Service...

Excerpt: “For more than a year, the Committee has been investigating potential breakdowns in the controlled substances supply chain which may have contributed to the nation’s opioid epidemic. Pharmaceutical manufacturers play a unique and critical role in this supply chain by researching and developing products for the consumer market as well as marketing such products after obtaining approval from the Food and Drug Administration (FDA).”

To read a copy of the letter to Insys Therapeutics, Inc., click here.

To read a copy of the letter to Mallinckrodt Pharmaceuticals, click here.

To...

Excerpt: "This rushed determination by EPA represented a lack of commitment to the process set forth in 2012. Thankfully, this Administration resumed a transparent and open process and in March 2017, NHTSA and EPA announced they would reopen the Midterm Evaluation and work together as originally intended. This joint Notice of Proposed Rulemaking represents a commitment to a process that enables full consideration of up-to-date scientific data, market trends, technological advancements, and stakeholder input. We applaud NHSTA and EPA for this productive step and thank you for your leadership...